Following the Supreme Court’s decision in Sandoz v Amgen, both drug makers have filed, in compliance with the Federal Circuit court’s order, supplemental briefs. These briefs state the parties’ opinions on the appropriate action to be taken after the Supreme Court remanded the case to the lower courts.
Following the Supreme Court’s recent decision in the case of Sandoz v Amgen, both drug makers this week filed supplemental briefs in compliance with a Federal Circuit court order. These briefs state the parties’ opinions on the appropriate action to be taken after the Supreme Court remanded the case to the lower courts.
In its brief, Amgen said that Sandoz’s refusal to provide its abbreviated Biologics License Application for its biosimilar filgrastim was a violation of the Biologics Price Competition and Innovation Act (BPCIA), and was therefore “unlawful” and “wrongful.” It stated that the failure of Sandoz to comply with the patent dance is sufficient to vacate the district court’s previous dismissal of Amgen’s claim against Sandoz under California’s laws concerning unfair competition. It also claimed that the BPCIA does not preempt any state law remedies for a failure to comply with the patent dance, because the BPCIA does not provide a remedy of its own for a failure to comply with its provisions. Furthermore, Amgen claims that Sandoz has waived any preemption defense in the past, so it should not be allowed to argue preemption now.
Sandoz, in its brief, said that the court should affirm the dismissal of Amgen’s claims under state laws, because, it claims, state laws are preempted by the BPCIA. “Allowing the 50 states to overlay their own disparate remedies onto the BPCIA’s complex procedural scheme would disrupt the careful balance struck by Congress,” Sandoz said. “As the Supreme Court recognized, Congress chose which remedies to provide and chose not to provide others.” Sandoz asked that the case be remanded directly to the district court rather than be made the subject of a separate appellate proceeding.
Ha Kung Wong, JD, told The Center for Biosimilars® in a recent interview, “[The Supreme Court] remanded the question to the Federal Circuit as to whether an injunction may be available under state law, and specifically whether an injunction for failure to provide the initial disclosures was available under California’s unfair competition law. That’s one question that was deliberately left unanswered by the Court in Sandoz.”
The issue of whether the BPCIA preempts remedies under state law could be informed by an amicus brief; as Big Molecule Watch reports, the United States is considering filing such a brief in the case to address the question of preemption. The court has extended the window for amicus brief filing until September 11, 2017.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.